
Fate Therapeutics Reports First Quarter 2025 Financial Results And Business Updates
(MENAFN- GlobeNewsWire - Nasdaq) Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus Erythematosus to be Featured in Oral Presentation at EULAR 2025 Congress in June Regenerative Medicine …